NCT02389920Unknown4 期
Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 入组人数
- 40
- 主要终点
- The rate of improvement of Dasatinib-related adverse events
研究概览
简要总结
Describe the purpose of the study: This study aims to evaluate the improvement of Dasatinib-related adverse events and to evaluate the treatment effect and safety by measuring the genetic response of nilotinib with nilotinib 400mg BID for 12 months in Philadelphia chromosome-positive chronic myeloid leukemia patients intolerant to Dasatinib.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women ≥ 19 years old
- •Performance status (ECOG) of 0, 1, or 2
- •Chronic phase or accelerated phase chronic myeloid leukemia being treated for more than two weeks, switch to nilotinib.
- •Appropriate target organ function defined as;
- •Bilirubin < 1.5 X ULN- Liver function test, AST (SGOT) and ALT (SGPT) < 2.5 X ULN- Creatinine < 1.5 X ULN- Serum amylase and lipase ≤ 1.5 X ULN- Alkaline phosphatase ≤ 2.5 X ULN (only if not related to tumor)
- •Women of childbearing potential must have a negative pregnancy test (urine or serum) within 7 days prior to the start of study drug administration.
- •Should have laboratory results as follows.
- •Potassium ≥ LLN- Magnesium ≥ LLN- Phosphorus ≥ LLN
- •Voluntary, signed and dated informed consent prior to any study procedures being performed
排除标准
- •Subjects with the T315I mutation
- •Mutation known to be associated with low sensitivity to nilotinib(e.g., Y253H, E255K, E255V, F359V),
- •Cardiac function abnormalities as follows are found.
- •FEVI < 45% or less than lower limit of normal of each center on ECG
- •QT interval cannot be measured on ECG
- •Complete right bundle branch block
- •Using a ventricular pacemaker
- •Congenital long QT syndrome or family history of long QT syndrome
- •Past or present clinically significant ventricular or atrial tachycardia
- •Clinically significant bradycardia at rest (< 50 beats/min)
- •Regardless of toxicity after Dasatinib intake, QTc > 480 msec (using the QTcF formula) at baseline ECG. If QTcF > 480 msec and electrolytes are not within the normal range, it is necessary to correct electrolytes and re-assess the patient's QTc. According to the result of QTc, the investigator makes a decision on the patient's enrollment.
- •Myocardial infarction within 12 months prior to the start of the study
- •Other clinically significant heart disease (e.g., unstable angina, congestive heart failure or uncontrolled hypertension)
- •Cytopathologically confirmed central nervous system lumbar puncture (spinal tapping is not needed if it is not suspected of association with central nervous system)
- •Severe or uncontrolled disease (e.g., uncontrolled diabetes mellitus, active or uncontrolled infection)
- •History of significant congenital or acquired, bleeding disorder unrelated to cancer
- •25% or more of bone marrow has been treated with prior radiotherapy
- •Not recovered from prior surgery or having a major surgery within 4 weeks from Day -1 of the study
- •Treated with other investigational product within 30 days
- •History of noncompliance with medical treatment or unable to voluntarily provide the written signed and dated informed consent
- •Other primary cancer which is currently clinically significant and requires active treatment
- •Currently treated with a strong CYP3A4 inhibitor (e.g., erythromycin, ketoconazole, itraconazol, voriconazol, clarithromycin, telithromycin, ritonavir, mibefradil), and the treatment cannot be stopped or switched to other drug before the start of study drug administration (For a complete list, refer to this link: http://medicine.iupui.edu/flockhart/table.htm.)
- •Gastrointestinal dysfunction or gastrointestinal disease that may significantly change the absorption of study drug (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass)
- •History of acute pancreatitis within the past 1 year or history of chronic pancreatitis
- •Acute or chronic uncontrolled liver, pancreas or severe renal disease unrelated to the disease
- •Currently treated with a drug which may prolong QT interval, and the treatment cannot be stopped or switched to other drug before the start of study drug administration (For a complete list of products which prolong QT interval, refer to http://www.torsades.org/medical-pros/drug-lists/printable-drug-list.cfm)
- •Pregnant women, breast-feeding women
研究组 & 干预措施
Nilotinib
Experimental
nilotinib 400mg BID for 12 months
干预措施: Nilotinib (Drug)
结局指标
主要结局
The rate of improvement of Dasatinib-related adverse events
时间窗: at 3 months of nilotinib treatment
次要结局
未报告次要终点
研究者
Chul Won Jung
Samsung Medical Center
Samsung Medical Center
相似试验
已完成
2 期
Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaPhiladelphia Chromsome Positive Acute Lymphoblastic LeukemiaNCT01528085Goethe University79
终止
1 期
An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)LeukemiaNCT02225574M.D. Anderson Cancer Center1
已完成
2 期
A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has SpreadMucosal Lentiginous MelanomaAcral Lentiginous Malignant MelanomaNCT01395121Institute of Cancer Research, United Kingdom29
已完成
4 期
A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)Chronic Myelogenous Leukemia - Chronic PhaseNCT04925141Chia Tai Tianqing Pharmaceutical Group Co., Ltd.62
已完成
4 期
Tasigna in Glivec-resistant or Intolerant Patients in CMLCMLNilotinibImatinib ResistantImatinib IntolerantNCT01206088Novartis Pharmaceuticals93